RxDoctor Payments Data

Vipul Brahmbhatt, MD

Family Medicine · Jeffersonville, INNPI 1275553778

Payments from drug & device makers

$1,561in general payments, 2019–2025

Across 44 payments — averaging $35.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$983
  • Merck$199
  • GSK$94
  • AstraZeneca$91
  • Johnson & Johnson$57
  • Pfizer$40
  • plus $97 from 5 others

What the payments were for

  • Travel & lodging$95761%
  • Food & beverage$60439%

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic5$983
Merck13$199
GSK7$94
AstraZeneca6$91
Johnson & Johnson4$57
Pfizer2$40
Nabriva Therapeutics, PLC3$36
Abbott1$23
Seqirus USA Inc1$16
Lilly USA, LLC1$13
Inogen, Inc.1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,561 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$87,048
Medicare patients
181
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$22,745
EliquisApixaban21$20,028
XareltoRivaroxaban11$12,701
BrilintaTicagrelor13$7,280
JanumetSitagliptin Phos/Metformin Hcl11$6,201
SymbicortBudesonide/Formoterol Fumarate17$4,792
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm16$3,331
Potassium Chloride130$2,574
Levothyroxine Sodium168$1,826
Albuterol Sulfate HfaAlbuterol Sulfate59$1,471
Atorvastatin Calcium212$1,382
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,259
VascepaIcosapent Ethyl13$1,138
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm14$751
Metoprolol Succinate66$726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$20,02821 claims
Johnson & JohnsonXarelto$57$12,70111 claims
AstraZenecaBrilinta, Symbicort$91$12,07330 claims
MerckJanumet$199$6,20111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →